A2T Stock Overview
A biomedical company, provides diagnostic services and medical treatments.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Atrys Health, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.13 |
| 52 Week High | €5.52 |
| 52 Week Low | €2.62 |
| Beta | 0.41 |
| 1 Month Change | 6.46% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -66.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| A2T | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.6% | 1.6% |
| 1Y | n/a | 1.6% | 7.3% |
Return vs Industry: Insufficient data to determine how A2T performed against the German Healthcare industry.
Return vs Market: Insufficient data to determine how A2T performed against the German Market.
Price Volatility
| A2T volatility | |
|---|---|
| A2T Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: A2T has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A2T's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 1,865 | Isabel Lozano Fernandez | www.atryshealth.com |
Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
Atrys Health, S.A. Fundamentals Summary
| A2T fundamental statistics | |
|---|---|
| Market cap | €274.88m |
| Earnings (TTM) | -€30.45m |
| Revenue (TTM) | €206.10m |
1.3x
P/S Ratio-9.0x
P/E RatioIs A2T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A2T income statement (TTM) | |
|---|---|
| Revenue | €206.10m |
| Cost of Revenue | €148.96m |
| Gross Profit | €57.15m |
| Other Expenses | €87.59m |
| Earnings | -€30.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 27.73% |
| Net Profit Margin | -14.77% |
| Debt/Equity Ratio | 76.1% |
How did A2T perform over the long term?
See historical performance and comparison